Abstract
Both breast and lung cancers are common malignancies and within the context of known genetic predispositions to breast cancer, no association has been made in linking the two diseases together. This does not exclude the possibility that such associations may exist that lie outside the known high-risk breast cancer families. To examine the likelihood of common genetic factors that could influence the risk of disease, two sets of consecutively collected tumor groups were examined for the 3020insC mutation in the NOD2/CARD15 gene. A total of 4107 consecutively collected breast cancer patients were assessed for the prevalence of the 3020insC mutation and compared to a consecutively collected series of 389 lung cancer patients and 2068 control samples. The results revealed that a proportion of breast cancer patients who had a first or a second degree relative diagnosed with lung cancer were more likely to harbour a change in NOD2/CARD15 compared to patients who had no relatives affected by lung cancer. Furthermore, this difference appeared to be specific to the breast and lung cancer subgroup since there was no difference in the frequency of the 3020insC allele in the consecutively collected lung cancer patients. In conclusion, it appears that the 3020insC mutation of the NOD2/CARD15 gene may be a genetic predisposing factor for aggregations of breast and lung cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brownson RC, Alavanja MC, 2000 Previous lung disease and lung cancer risk among women (United States)Cancer Causes Control 11: 853–858
Littman AJ, Thornquist MD, White E, Jackson LA, Goodman GE, Vaughan TL, 2004 Prior lung disease and risk of lung cancer in a large prospective study Cancer Causes Control 15: 819–827
Knowles H, Leek R, Harris AL: Macrophage infiltration and angiogenesis in human malignancyNovartis Found Symp 256: 189 –200; discussion 200–204, 259–269, 2004
Denkert C, Winzer KJ, Hauptmann S, 2004 Prognostic impact of cyclooxygenase−2 in breast cancerClin Breast Cancer 4: 428–433
Kurzawski G, Suchy J, Kladny J, Grabowska E, Mierzejewski M, Jakubowska A, Debniak T, Cybulski C, Kowalska E, Szych Z, Domagala W, Scott RJ, Lubiński J, 2004 The NOD2 3020insC mutation and the risk of colorectal cancer Cancer Res 64: 1604–1606
Papaconstantinou I, Theodoropoulos G, Gazouli M, Panoussopoulos D, Mantzaris GJ, Felekouras E, Bramis J, 2005 Association between mutations in the CARD15/NOD2 gene and colorectal cancer in a Greek populationInt J Cancer 114: 433–435
Huzarski T, Lener M, Domagala W, Gronwald J, Byrski T, Kurzawski G, Suchy J, Chosia M, Woyton J, Ucinski M, Narod SA, Lubinski J, 2005 The 3020insC allele of NOD2 predisposes to early-onset breast cancerBreast Cancer Res Treat 89: 91–93
Lubiński J, Huzarski T, Kurzawski G, Suchy J, Masojć B, Mierzejewski M, Lener M, Domagała W, Chosia M, Teodorczyk U, Mędrek K, Dębniak T, Złowocka E, Gronwald J, Byrski T, Grabowska E, Nej K, Szymańska A, Szymańska J, Matyjasik J, Cybulski C, Jakubowska A, Górski B, Narod SA, 2005 The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs Hered Cancer Clin Pract 3: 59–63
Bonen DK, Cho JH, 2003 The genetics of inflammatory bowel disease Gastroenterology 124: 521–536
Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP, 2004 Differential effects of NOD2 variants on Crohn’s disease risk and phenotype in diverse populations: a metaanalysis Am J Gastroenterol 99: 2393–2404
Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G, 2001a Nod2, a Nod1/Apaf−1 family member that is restricted to monocytes and activates NF-kappaB J Biol Chem 276: 4812–4818
Inohara N, Ogura Y, Chen FF, Muto A, Nunez G, 2001 Human Nod1 confers responsiveness to bacterial lipopolysaccharidesJ Biol Chem 276: 2551–2554
Schreiber S, Nikolaus S, Hampe J, 1998 Activation of nuclear factor kappa B inflammatory bowel diseaseGut 42: 477–484
Ellis RD, Goodlad JR, Limb GA, Powell JJ, Thompson RP, Punchard NA, 1998 Activation of nuclear factor kappa B in Crohn’s diseaseInflamm Res 47: 440–445
Fiocchi C, 1998 Inflammatory bowel disease: etiology and pathogenesisGastroenterology 115: 182–205
Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH, 2001b A frameshift mutation in NOD2 associated with susceptibility to Crohn’s diseaseNature 411: 603–606
Maeda S, Hsu LC, Liu H, Bankston LA, Iimura M, Kagnoff MF, Eckmann L, Karin M, 2005 Nod2 mutation in Crohn’s disease potentiates NF-kappaB activity and IL−1beta processingScience 307: 734–738
Miller SA, Dykes DD, Polesky HF, 1998 A simple salting out procedure for extracting DNA from human nucleated cellsNucleic Acids Res 16: 1215
Alhopuro P, Ahvenainen T, Mecklin JP, Juhola M, Jarvinen HJ, Karhu A, Aaltonen LA, 2004 NOD2 3020insC alone is not sufficient for colorectal cancer predispositionCancer Res 64: 7245–7247
Dębniak T, Kurzawski G, Huzarski T, Byrski T, Gronwald J, Dębniak B, Rozmiarek A, Dziuba I, Zlowocka E, Suchy J, Górski B, Cybulski C, Mierzejewski M, Masojć B, Mędrek K, Oszurek O, Lubiński J, 2005 NOD2 variants and the risk of malignant melanomaEur J Cancer Prev 14: 143–146
Munkholm P, 2003 Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel diseaseAliment Pharmacol Ther 2: 1–5
Yu HG, Yu LL, Yang Y, Luo HS, Yu JP, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F, 2003 Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesisOncology 65: 37–45
Bailey-Wilson JE, Amos CI, Pinney SM, Petersen GM, de Andrade M, Wiest JS, Fain P, Schwartz AG, You M, Franklin W, Klein C, Gazdar A, Rothschild H, Mandal D, Coons T, Slusser J, Lee J, Gaba C, Kupert E, Perez A, Zhou X, Zeng D, Liu Q, Zhang Q, Seminara D, Minna J, Anderson MW, 2004 A major lung cancer susceptibility locus maps to chromosome 6q23–25Am J Hum Genet 75: 460–474
Acknowledgements
M. Lener, J. Castaneda, J. Suchy, K. Nej-Wołosiak are recipients of a scholarship from the Postgraduate School of Molecular Medicine affiliated with the Medical University of Warsaw and were partially supported by a grant from The Leopold Kronenberg Foundation. We would like to acknowledge the contributions of B.␣Czeszyńska, R. Czajka, W. Fabian, M. Foszczyńska-Kłoda, E. Jaworowska, J. Kładny, E. Kowalska, A.␣Lenczewski, J. Menkiszak, A. Raczyński, I. Rzepka-Górska, A. Sikorski, T. Starzyńska, M. Uciński, A.␣Witek, J. Woytoń in providing control samples.
Author information
Authors and Affiliations
Additional information
Address for offprints and correspondence: Marcin Lener, International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, ul. Połabska 4, 70-115 Szczecin, Poland; Tel.:/Fax: +48-91-466-15-33; E-mail: marcinlener@poczta.onet.pl
Rights and permissions
About this article
Cite this article
Lener, M., Oszutowska, D., Castaneda, J. et al. Prevalence of the NOD2 3020insC mutation in aggregations of breast and lung cancer. Breast Cancer Res Treat 95, 141–145 (2006). https://doi.org/10.1007/s10549-005-9057-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-005-9057-z